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Abstract 
Background: Rapid diagnostic tests (RDTs) are today the most widely used method for malaria diagnosis and are rec‑
ommended, alongside microscopy, for the confirmation of suspected cases before the administration of anti‑malarial 
treatment. The diagnostic performance of RDTs, as compared to microscopy or PCR is well described but the actual 
analytical sensitivity of current best‑in‑class tests is poorly documented. This value is however a key performance 
indicator and a benchmark value needed to developed new RDTs of improved sensitivity.
Methods: Thirteen RDTs detecting either the Plasmodium falciparum histidine rich protein 2 (HRP2) or the plasmodial 
lactate dehydrogenase (pLDH) antigens were selected from the best performing RDTs according to the WHO–FIND 
product testing programme. The analytical sensitivity of these products was evaluated using a range of reference 
materials including P. falciparum and Plasmodium vivax whole parasite samples as well as recombinant proteins.
Results: The best performing HRP2‑based RDTs could detect all P. falciparum cultured samples at concentrations as 
low as 0.8 ng/mL of HRP2. The limit of detection of the best performing pLDH‑based RDT specifically detecting P. vivax 
was 25 ng/mL of pLDH.
Conclusion: The analytical sensitivity of P. vivax and Pan pLDH‑based RDTs appears to vary considerably from product 
to product, and improvement of the limit‑of‑detection for P. vivax detecting RDTs is needed to match the perfor‑
mance of HRP2 and Pf pLDH‑based RDTs for P. falciparum. Different assays using different reference materials produce 
different values for antigen concentration in a given specimen, highlighting the need to establish universal reference 
assays.
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Background
The development of point-of-care lateral flow immuno-
chromatographic assays in the mid 1990s for the detec-
tion of malaria parasites in minute amounts of capillary 
blood has radically changed the diagnosis of this parasitic 
disease in endemic areas. These tests, commonly referred 
to as rapid diagnostic tests (RDTs), have established 
themselves as an extremely valuable alternative to the 
examination of stained blood smears by light microscopy. 
While light microscopy remains a method of choice for 
malaria diagnosis in many areas, the use of quality-con-
trolled RDTs is considered adequate and recommended 
by the World Health Organization (WHO) for the par-
asitological confirmation of suspected malaria cases 
[1]. With approximately 314 million units sold in 2014, 
malaria RDTs represent a major commodity in the fight 
against malaria and the primary method for malaria diag-
nosis in comparison to the estimated 203 million sus-
pected cases tested by microscopy worldwide in 2014 [2].
RDTs are affordable, with retail prices varying between 
0.2 and 1.0 US dollar and an estimated cost of diagnosis 
between 1.0 and 2.0 US dollars [3, 4]. Other key advan-
tages are their simplicity, which enables their use in a 
point-of-care mode by minimally trained individuals, and 
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the rapidity with which test results can be obtained, typi-
cally within 20 min or less. Light microscopy is not nec-
essarily much more expensive, with a cost of diagnosis 
estimated between 1.0 and 2.0 US dollars [3]. However, it 
is more complex to implement and to maintain at a good 
quality level, requiring a microscope and a laboratory to 
stain and read blood smears, and is critically dependent 
on the training and performance level of the microscopist 
to generate accurate results.
Malaria RDTs typically consist of a plastic cassette 
enclosing a nitrocellulose membrane strip, at the bottom 
of which are placed lysing agents and dye-labelled anti-
bodies specifically recognizing a Plasmodium antigen of 
interest. Upon the addition of blood (typically 10  µL or 
less) and buffer to the bottom of the strip, the red blood 
cells lyse, mix with the labelled antibodies, and migrate 
along the membrane strip by capillarity toward a fine 
line of bound antibodies. If the antigen of interest is pre-
sent in the investigated blood sample at a sufficiently 
high concentration, the antigen-labelled antibody com-
plexes will be captured on this line and the accumulated 
dye will become visible to the naked eye. A control line, 
coated with either the antigen of interest or antibodies 
recognizing directly the labelled antibody, is also typically 
included to assess the integrity of individual RDT rea-
gents and their correct diffusion across the nitrocellulose 
membrane.
Current commercial malaria RDTs target one or more 
of three standard Plasmodium proteins. These are his-
tidine rich protein 2 (HRP2) and two enzymes of the 
Plasmodium glycolytic pathway: aldolase and plasmo-
dial lactate dehydrogenase (pLDH). HRP2 is specific to 
Plasmodium falciparum whereas aldolase and pLDH 
are expressed in all five human-infecting Plasmodium 
spp. and allow, in principle, the detection of all of them 
(pan-RDT). In addition, and because pLDH is not fully 
conserved across Plasmodium species, the selection of 
species-specific epitopes has allowed the development of 
antibodies recognizing specifically P. falciparum pLDH 
(Pf-pLDH), Plasmodium vivax pLDH (Pv-pLDH) or col-
lectively P. vivax, Plasmodium ovale, and Plasmodium 
malariae pLDH (Pvom-pLDH). HRP2-based RDTs are 
the main product type for the detection of P. falciparum, 
while species-specific detection of P. vivax, the second 
most prevalent malaria species in humans, requires the 
use of Pv-pLDH-based RDTs.
The performance of RDTs is very often analysed from 
the clinical point-of-view: the capacity of RDTs to iden-
tify correctly malaria positive and negative samples is 
evaluated in comparison to a reference method, such as 
light microscopy or PCR, and diagnostic sensitivity and 
specificity values are reported with associated confi-
dence intervals [5, 6]. Little is known however, about the 
analytical performance of RDTs, especially the analytical 
sensitivity, which corresponds to the lowest detectable 
concentration of the target analyte. This parameter is 
especially important as it directly relates to the capacity 
of malaria RDTs to detect and correctly diagnose malaria 
parasites early during the course of an infection, which 
is required rapidly to alleviate symptoms and prevent as 
much as possible, the appearance of gametocytes and 
the transmission of parasites. The analytical sensitiv-
ity of current RDTs is also a key benchmark value when 
considering the development of RDTs with improved 
sensitivity, which might enable the diagnosis of not only 
clinical cases of malaria but also low density and asymp-
tomatic infections [7], which are currently considered to 
be beyond the detection limit of standard malaria RDTs.
In this study, the analytical sensitivity of 13 RDTs 
selected amongst the best performing ones were evalu-
ated using a range of reference materials calibrated for 
their HRP2 or pLDH content. The limits of detection, 
expressed in target analyte concentrations, for these 
products are reported and the implications of these val-
ues on the performance on malaria RDTs are discussed.
Methods
Rapid diagnostic tests selection
The selection of the best-in-class RDTs was based on the 
results of the WHO–FIND product testing programme 
(Rounds 1–6), which has evaluated the performance of 
171 unique RDT products on malaria samples at stand-
ardized parasitaemia (200 and 2000 parasites/µL) [8]. 
The reactivity of each RDT against P. falciparum or P. 
vivax isolates is reported as a panel detection score (PDS) 
which reflects the percentage of positive samples cor-
rectly detected when tested in duplicate by two distinct 
lots. RDTs are also tested against a panel of clean nega-
tive samples from which a false-positive rate is derived. 
Finally, the percentage of invalid results is also available.
The following selection criteria were used to identify 
the best-in-class HRP2 and pLDH (Pv-pLDH, Pf-pLDH, 
Pvom-pLDH and Pan-pLDH) products. For HRP2-based 
RDTs, a PDS ≥ 85% for P. falciparum samples at 200 p/µL 
and a false positivity rate <0.5% was required. For pLDH-
based RDTs, the selection criteria were not as stringent 
as for HRP2-based RDTs, because of the lower number 
of existing products and the overall lower performance 
of RDTs detecting this antigen. For each type of pLDH-
detecting RDT, a PDS ≥ 75% for P. falciparum or P. vivax 
samples at 200 p/µL and a false positivity rate  <5% was 
required. When products with identical performance 
were available, the selection was made to maximize the 
diversity of product manufacturers. The identity of the 
selected RDTs was anonymized by numbering 1–13 as 
the goal of this study was not to evaluate the performance 
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of specific products or manufacturers but to report the 
analytical sensitivity of current best-in-class RDTs.
HRP2 reference materials
Plasmodium falciparum culture samples from three labo-
ratory strains and a recombinant HRP2 protein expressed 
in Escherichia coli (Microcoat GmbH, Germany, lot 
number ESS_1426, manufactured July 2014) based on 
the HRP2 sequence of the W2 P. falciparum strain, were 
selected as HRP2 reference materials. The Benin I, Santa 
Lucia, and PH1 strains were cultured under standard 
hypoxic conditions as previously reported [9]. Cultures 
in exponential growth phase were harvested, infected 
red blood cells were spun down, aliquoted, and frozen 
at −80  °C for long term storage. The HRP2 concentra-
tions contained within the cultured samples were meas-
ured by a commercially available ELISA (see below) and 
twofold serial dilutions were prepared using malaria 
negative whole blood to obtain samples at the following 
HRP2 concentrations: 3.2, 1.6, 0.8, 0.4, 0.2, 0.1, 0.05 and 
0.025 ng/mL.
pLDH reference materials
Plasmodium falciparum culture samples, P. vivax iso-
lates from malaria patients (to circumvent the absence 
of P. vivax culture system), as well as P. falciparum and 
P. vivax recombinant pLDH proteins were used as refer-
ence materials. The FCQ79, W2, and PH1 P. falciparum 
strains were cultured under standard hypoxic conditions 
(of note these partially differ from the strains selected 
for the evaluation of HRP2 RDTs because of the limited 
strain availability at the respective laboratories where the 
two types of RDTs were evaluated). Cultures in expo-
nential growth phase were harvested, infected red blood 
cells were spun down, aliquoted, and frozen at −80 °C for 
long term storage. Plasmodium vivax isolates were col-
lected from symptomatic adult volunteers with a P. vivax 
mono-species infection as confirmed by microscopy dur-
ing a specimen collection campaign organized in April 
2016 in the area of Iquitos (Peru). The study protocol was 
approved by the institutional review board the Universi-
dad Peruana Cayetano Heredia (Lima, Peru).
A volume of venous whole blood was collected, antico-
agulated using EDTA, aliquoted, and frozen within 24 h 
at −80  °C for long term storage. Five samples, referred 
to here as Pv1–Pv5, were selected for this study and 
confirmed to be P. vivax mono-species infections by 
nested PCR, according to a previously published proto-
col [10]. Purified recombinant P. falciparum and P. vivax 
pLDH proteins expressed in E. coli were obtained from 
MyBioSource (USA, ref. MBS319810 and MBS319848, 
respectively) and are referred here as Pf-pLDH EC and 
Pv-pLDH EC. Purified recombinant P. falciparum and P. 
vivax pLDH proteins expressed in insect cells were pro-
duced by ReliaTech GmbH (Germany) and are referred 
here as Pf-pLDH EUK and Pv-pLDH EUK. The pLDH 
concentrations of the culture samples, field isolates and 
recombinant proteins were measured by a commercially 
available ELISA (see below) to prepare serial dilutions 
using malaria negative whole blood. Ten-fold serial dilu-
tions ranging from 5000 to 0.5 ng/mL were prepared for 
an initial evaluation of the RDT analytical sensitivities. 
Additional twofold serial dilutions, with five dilutions 
each, centred around the 10-fold dilution values, were 
further prepared to obtain more precise estimates of the 
RDT analytical sensitivities. Series ranged from 2000 to 
125  ng/mL, 200 to 12.5  ng/mL, 20 to 1.25  ng/mL, and 
2 to 0.125 ng/mL.
HRP2 quantitative ELISA
The quantification of HRP2 content within reference 
materials was done using the Malaria Ag Pf ELISA 
kit (ref. 05EK50) manufactured by Standard Diagnos-
tics (South Korea). ELISAs were performed as recom-
mended by the manufacturer, with minor modifications 
to improve sensitivity. The sample incubation step was 
performed at 37 °C with agitation at 600 rpm using a 96 
well multi-plate thermo-shaker (PHMP4, Grant-bio) and 
substrate development time increased from 10 to 20 min. 
Absorbances at 450 and 620 nm were read using a Micro-
tek DS dynamic microplate spectrophotometer (Bio-Tek).
A purified HRP2 recombinant protein expressed in E. 
coli (Microcoat GmbH, Germany, lot ESS_1426, manu-
factured July 2014) based on the allele of the W2 P. 
falciparum laboratory strain (type B) of known concen-
tration, as determined by absorbance at 280  nm, was 
used as reference standard. Briefly, eight point serial 
dilution standard curves were tested in quadruplicate 
and the average absorbance values were used to gener-
ate both arithmetic and logarithmic calibration curves in 
Excel 2010 (Microsoft, version 14.0.7106.5003). Selected 
points from the logarithmic and arithmetic curves were 
used to plot straight line graphs and the applicable trend 
line equations used to calculate HRP2 concentrations 
from mean optical density (OD) readings recorded for 
each test sample. Each test sample of unknown concen-
tration was assessed in duplicate at three serial twofold 
dilutions, and the OD values for each dilution were aver-
aged to obtain the mean OD. The resulting calculated 
sample HRP2 concentrations were then multiplied out 
by the applicable dilution factors and these three final 
concentration values averaged again to give a final HRP2 
concentration for each test sample. Samples with absorb-
ance values out of the range of the standard curve were 
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re-assayed at adjusted dilutions. Final concentration val-
ues were the average of at least three independent assays 
for all samples of unknown concentrations.
pLDH quantitative ELISA
The quantification of the pLDH content within refer-
ence materials was done using the Qualisa Malaria kit 
(ref. 40903480) from Qualpro Diagnostics (India). This 
kit is an ELISA test based on the quantification of pLDH 
samples with immobilized pan-specific anti-pLDH cap-
ture monoclonal antibody on 96-well plates that can be 
used for field and cultured Plasmodium spp. samples 
or purified recombinant forms of pLDH. ELISAs were 
performed as recommended by the manufacturer, with 
minor modifications. The antibody reagent and sample 
diluent were added to the plate wells before the blood 
samples. The sample incubation step was extended from 
30 min to 1 h and the detection step was shortened from 
30 to 20  min. Washing steps were performed using an 
ELx405 Microplate Washer (Bio-Tek). The absorbances 
at 450 and 620 nm were read using an Epoch Microplate 
Spectrophotometer EPOCH (Bio-Tek).
A purified Pv-pLDH recombinant protein prepared by 
MicroMol GmbH (Germany) of known concentration, as 
determined by absorbance at 280 nm, was used as a ref-
erence standard in the ELISA. Briefly, eight point serial 
dilution standard curves were tested in triplicate and the 
average absorbance values and expected pLDH concen-
tration were used to generate a five-parameter logistic 
equation using GraphPad Prism 6 (GraphPad Software). 
Each test sample of unknown concentration was assessed 
in duplicate at three serial twofold dilutions, and the OD 
values for each dilution were averaged to obtain the mean 
OD. The resulting calculated sample pLDH concentra-
tions were then multiplied out by the applicable dilution 
factors and these three final concentration values aver-
aged again to give a final pLDH concentration for each 
test sample. Samples with absorbance values out of the 
range of the standard curve were re-assayed at adjusted 
dilutions. Final concentration values were the average 
of at least three independent assays for all samples of 
unknown concentrations.
Rapid diagnostic tests evaluation
The reference materials described above and prepared in 
malaria negative whole blood were used to evaluate the 
reactivity of the selected RDTs according to the respec-
tive manufacturer’s recommendations. For each product, 
a single lot was sourced directly from the manufactur-
ing company, stored according to recommendations and 
used before its expiration date. RDTs were always 
tested in duplicate and the test line colour intensity was 
recorded according to a visual scale ranging from 0 (no 
signal) to 4 (strong intensity). An average score above 0 
was classified as a positive test result while an average 
score of 0 was classified as negative. The HRP2-based 
RDTs were evaluated at the Hospital for Tropical Dis-
eases laboratory (London, England) and the pLDH-based 
RDTs were evaluated at the Barcelona Institute for Global 
Health (Barcelona, Spain). At each laboratory, duplicate 
RDTs were prepared and read by the same technician. 
A workshop was organized to harmonize the scoring at 
both laboratories and ensure results comparability.
Results
Rapid diagnostic tests selection
Following the pre-defined criteria, five HRP2- and eight 
pLDH-based RDTs were selected (Table  1, numbered 
1–13 according to the antigen of interest and then by 
decreasing PDS for the relevant antigen). Out of the eight 
pLDH products selected, three detect Pv-pLDH (RDTs 
6, 7, and 8), two detect Pf-pLDH (RDTs 10 and 11), one 
detects Pvom-pLDH (RDT 9) and three detect Pan-
pLDH (RDTs 10, 12, and 13).
Of note, the independent selection of the best-in-
class HRP2- and pLDH-based RDTs showed no overlap 
despite the relatively large number of combination RDTs 
detecting simultaneously HRP2 and some variants of 
pLDH that have been evaluated in the WHO-FIND prod-
uct testing programme (64 out 129 products).
Analytical sensitivity of best‑in‑class HRP2‑based rapid 
diagnostic tests
Five HRP2-based RDTs (RDTs 1–5) were evaluated using 
samples from three P. falciparum laboratory strains and 
one purified HRP2 recombinant protein. The lowest 
HRP2 concentrations detected from the twofold serial 
dilutions are reported in Table  2 for each combination. 
The lowest HRP2 concentration at which all three P. fal-
ciparum cultured strains tested here could be detected 
was 0.8 ng/mL for RDT 1, RDT 2, RDT 4, and RDT 5 and 
1.6 ng/mL for RDT 3. The overall lowest HRP2 concen-
tration detected was 0.4  ng/mL, as observed for three 
out of five RDTs when tested with samples from the PH1 
strain. Very similar values were observed with the recom-
binant HRP2 protein, with limits of detection ranging 
from 0.8 to 1.6 ng/mL.
Analytical sensitivity of best‑in‑class pLDH‑based rapid 
diagnostic tests
Eight pLDH-based RDTs were tested (RDTs 6–13) on 
five P. vivax isolates, three P. falciparum culture strains, 
as well as on P. falciparum and P. vivax purified recombi-
nant proteins expressed in E. coli (Pf-pLDH EC and Pv-
pLDH EC) or insect cells (Pf-pLDH EUK and Pv-pLDH 
EUK). The lowest pLDH concentrations detected from 
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the twofold serial dilutions are reported in Table  3 for 
each combination.
Pv-pLDH specific RDTs could detect all five P. vivax 
samples at a concentration as low as 50 ng/mL (RDT 7) 
or 25 ng/mL (RDT 6 and RDT 8). The lowest pLDH con-
centration detected when testing P. vivax samples was 
12.5 ng/mL (RDT 6). Very similar values were seen with 
recombinant pLDH proteins, with both Pv-pLDH pro-
teins showing limits of detection ranging between 10 and 
25 ng/mL. The single RDT with a Pvom-pLDH test line 
(RDT 9) could detect the P. vivax samples at concentra-
tions between 5 and 12.5  ng/mL of Pv-pLDH. The lim-
its of detection for the recombinant Pv-pLDH proteins 
expressed in E. coli and insect cells were below and above 
these values at 2.5 and 20 ng/mL, respectively.
Pf-pLDH RDTs could detect P. falciparum culture 
samples at much lower concentrations compared to Pv-
pLDH RDT detecting P. vivax samples, with RDT 11 
detecting all three P. falciparum strains tested at concen-
trations of 1 ng/mL or lower. RDT 10 detected these sam-
ples at concentrations ranging between 2.5 and 5 ng/mL. 
The limit of detection for recombinant Pf-pLDH proteins 
was at least one order of magnitude above these values at 
100 ng/mL (RDT 10) and 10 ng/mL (RDT 11).
Three RDTs had Pan-pLDH test lines (RDTs 10, 12, and 
13). When tested using P. vivax reference materials, large 
differences in the limit of detection were observed. At 
least 1000 ng/mL was required for RDT 10 to detect all 
P. vivax samples or recombinant proteins, 50 ng/mL for 
RDT 12 and 12.5 ng/mL for RDT 13. When considering 
only P. vivax samples, RDT 13 could detect all five with 
a concentration as low as 10 ng/mL. The limits of detec-
tion of the P. falciparum samples were more consistent 
between these three RDTs. All three P. falciparum cul-
ture strains could be detected at 5, 50 and 10 ng/mL by 
RDT 10, RDT 12, and RDT 13, respectively. For recom-
binant proteins, it required between 20 and 50 ng/mL to 
achieve the same.
Observations on RDT analytical specificities
Species cross-reactivity issues with pLDH-based RDTs 
have been reported previously in the literature [11]. The 
purpose of this study was not to directly evaluate this ele-
ment of the performance of RDTs, yet the serial dilutions 
Table 1 Selected RDTs
a The performance of both test lines of this RDT were selected (as per the selection criteria outlined in the “Methods”) for evaluation
RDT Manufacturer PDS for P. falciparum 
at 200 p/µL
PDS for P. vivax 
at 200 p/µL
False‑positivity  
rate
Antigen  
of interest
Additional 
antigen
1 A 95.0% n/a 0% HRP2 –
2 B 95.0% n/a 0.4% HRP2 –
3 C 90.8% 94.1% 0% HRP2 Pv‑pLDH
4 D 86.9% n/a 0% HRP2 –
5 B 85% 74.3% 0% HRP2 Pan‑pLDH
6 E 92.9 100% 0.5% Pv‑pLDH HRP2
7 F 79.6% 100% 1.5% Pv‑pLDH HRP2
8 A 96% 95% 0% Pv‑pLDH HRP2
9 C 89.8% 91.2% 0.3% Pvom‑pLDH HRP2
10 C 88.9% 91.4% 1.3% Pf‑PLDH, Pan‑pLDHa –
11 A 87.9% n/a 0% Pf‑pLDH HRP2
12 G 77% 100% n/a Pan‑pLDH –
13 C 90% 94.3% 1.5% Pan‑pLDH HRP2
Table 2 Analytical sensitivity of selected HRP2-based RDTs
Sample type Sample HRP2
RDT 1 (ng/mL) RDT 2 (ng/mL) RDT 3 (ng/mL) RDT 4 (ng/mL) RDT 5 (ng/mL)
P. falciparum culture Benin I 0.8 0.8 1.6 0.8 0.8
Santa Lucia 0.8 0.8 1.6 0.8 0.8
PH1 0.4 0.8 0.8 0.4 0.4
Recombinant protein rHRP2 (W2) 0.8 1.6 1.6 0.8 0.8
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of the pLDH reference materials were set at a relatively 
high initial concentration, 5000  ng/mL, to detect any 
overt specificity issues.
Reference materials containing whole parasites (i.e. P. 
falciparum cultured samples and P. vivax field samples) 
did not trigger any false positive reaction when tested at 
concentrations as high as 5000  ng/mL with any pLDH 
RDT, i.e. P. falciparum samples were only detected by 
Pan-pLDH or Pf-pLDH test lines, while P. vivax sam-
ples were only detected by Pv-pLDH, Pvom-pLDH and 
Pan-pLDH test lines. The pLDH recombinant proteins 
expressed in eukaryotic cells also generated only true 
positive reactions. In contrast, some false positive reac-
tions were seen with the recombinant pLDH proteins 
expressed in E. coli (Table  3). Pf-pLDH EC at 5000  ng/
mL triggered positive reactions on the Pv-pLDH test 
line of RDT 6 and on the Pvom-pLDH test line of RDT 
9. Pv-pLDH EC protein was detected at a concentra-
tion as low as 500  ng/mL by the Pf-pLDH test line of 
RDT 10. More surprisingly, all recombinant pLDH pro-
teins tested, that were expressed in E. coli or insect cells, 
showed some level of cross-reactivity with the HRP2 test 
lines of the pLDH-based RDTs tested here (Additional 
file 1: Table S1). While the recombinant pLDH proteins 
expressed in insect cells were recognized by the HRP2 
test lines of RDT 9 and 13, though not at concentra-
tions below 5000  ng/mL, recombinant pLDH proteins 
expressed in E. coli were detected by HRP2 test lines at 
concentrations as low as 50 ng/mL by some RDTs (RDT 
8, RDT 9 and RDT 13).
Discussion
In this study, the analytical sensitivity of 13 malaria RDTs 
classified amongst the best performing products accord-
ing to the results of the WHO–FIND product testing 
programme is reported [8]. A number of factors directly 
influence the performance of RDTs, including the anti-
body characteristics and stability, the antibody immobi-
lization technique, the nitrocellulose type and treatment. 
The values reported here are expressed in target analyte 
concentration and not parasite density to provide a direct 
measurement of the limit of detection of current best 
RDTs. While blood stage malaria infections are normally 
characterized by a parasitaemia expressed typically in 
percentage of parasitized red blood cells or in parasites 
detected per µL of blood, this value is less appropriate 
for RDTs since these are not detecting parasites them-
selves but amounts of target analyte produced by these 
parasites.
Five HRP2-based RDTs and eight pLDH-based RDTs 
were selected. This study focuses on these two analytes 
as the vast majority of current RDTs are based on the 
detection of HRP2 for the identification of P. falciparum 
infections, or on some combination of the pLDH iso-
forms for the pan or species-specific detection of the 
human-infecting Plasmodium species. Detection of the P. 
vivax pLDH isoform is also currently the only approach 
specifically to identify a P. vivax infection by RDT, which 
is of importance in areas of P. vivax and P. falciparum 
co-endemicity and where the recommended treatment 
guidelines are not identical for these species.
The HRP2-based RDTs tested here displayed very 
similar analytical sensitivities, with four out of five RDTs 
achieving the detection of all three P. falciparum strains 
tested at HRP2 concentrations down to 0.8 ng/mL. Inter-
estingly, four out of five RDTs systematically detected 
the PH1 strain at a lower HRP2 concentrations than the 
Benin I and Santa Lucia strains. HRP2 is a polymorphic 
antigen, characterized by variable copy numbers of spe-
cific repetitive motifs and an earlier study suggested that 
a correlation might exist between the total number of 
some of these repeats and the capacity of RDTs to detect 
specific isoforms [12]. Based on this criterion, HRP2 iso-
forms can be classified into three types, A, B, and C, with 
the number of these specific elements and the detectabil-
ity by RDTs being supposedly higher for type C than B 
and for type B than A. These results appear to be in line 
with this suggested correlation as PH1, a type C strain, 
is apparently detected by the RDTs tested here at lower 
concentrations than Benin I and Santa Lucia samples, 
which are type A and type B strains, respectively. How-
ever, the low number of strains tested here means that 
further data are required to support this hypothesis, 
especially as a study evaluating a larger number of P. fal-
ciparum isolates did not confirm the correlation between 
the A, B, and C type HRP2 classification and the detect-
ability by RDTs, leaving the relevance of this classification 
unclear [13].
The relationship between HRP2 blood level and the 
peripheral parasitaemia of infected individuals is weak. 
Some studies reported a lack of correlation between these 
two parameters [14], while others reported limited corre-
lations [15]. For this reason, it is not possible to translate 
directly the analytical sensitivity of HRP2-based RDTs 
reported here into a parasite density threshold. The three 
products with Pan-pLDH test lines showed contrasting 
results when tested with wild type P. vivax samples, with 
an overall detection limit of 10 ng/mL (RDT 13), 50 ng/
mL (RDT 12), and 1000 ng/mL (RDT 10), suggesting that 
the sensitivity of Pan-pLDH test lines is very much prod-
uct-dependent. The limit of detection of Pv-pLDH test 
lines of P. vivax isolates was more consistent with two 
products at 25 ng/mL and the third one at 50 ng/mL and 
in line with values reported in a previous study [16].
Similar to HRP2, the lack of a robust correlation 
between pLDH protein concentration and parasitaemia 
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[16] does not allow expression of these results in para-
site densities. RDT performance observed in this study 
using recombinant proteins is globally in line with that 
observed when using whole parasites from cultured sam-
ples or patient isolates that contain native HRP2 or pLDH 
proteins. One exception, however, is the higher LODs 
observed when testing Pf-pLDH RDTs with Pf-pLDH 
E. coli and eukaryotic recombinant proteins. Another 
observation was the false positive results obtained when 
testing pLDH recombinant proteins expressed in E. coli. 
The fact that these proteins exhibit a higher level of false 
positive reactions when tested on RDTs designed to 
detect a different species suggests that proteins expressed 
in a prokaryotic system might not be representative of 
native proteins found within whole parasites and that 
results generated using such proteins should be consid-
ered with caution. The fact that cross-reactivity and false 
positive results were observed only with recombinant 
proteins and not with samples containing native proteins 
suggests that these observations are not a cause for con-
cern for the performance of RDTs on clinical samples. 
This suggest however that the clinical relevance of quality 
control materials based on purified recombinant protein 
should be carefully validated.
It is worth noting that the analytical sensitivity values 
reported in this study have been measured in reference 
laboratories and these are likely to represent best-case 
scenarios as any potential degradation due to product 
transportation and storage in endemic settings or reading 
errors by end users are avoided here.
There are currently no universal reference assays or 
calibrators for the quantification of HRP2 and pLDH. For 
this reason, it is not possible to establish direct compari-
sons between the values reported here, measured using 
a specific assay and calibrator combination, with those 
reported in other studies that have utilized a different set 
of methodologies. This highlights the need to establish 
universally applicable reference tools in order to stand-
ardize the units by which antigen concentrations are 
measured in future evaluations.
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